Slay Sarcoma Research Initiative (SSRI)

Slay Sarcoma Research Initiative was incorporated December 31st, 2015 and became a non-profit 501(c)3 approved organization on June 6th, 2016.

The sole mission of the SSRI Inc. is to find a cure for leiomyosarcoma.  This will be accomplished by promoting awareness, fund-raising for scientific grant award distribution, and donations to organizations and individuals to this end.


Date RFP Issued: January 15, 2017    Clinical Area: Leiomyosarcoma

Link to full RFP: Leiomyosarcoma Research Information

Link to grant application: Download PDF


Leiomyosarcoma remains a difficult disease to treat despite the use of modalities such as chemotherapy and radiation. Knowledge gaps exist in areas concerning the etiology, progression and treatment of LMS. New biologic medications that target specific components of the immune system are recent discoveries that may prove to be useful in this disease. Combination of modalities may ultimately be needed in combating LMS, although specific agents, dosing and sequence of interventions need to be determined.    The intent of this RFP is to encourage research organizations to submit a letter of intent (LOI)    that is related to basic or clinical LMS research focusing on etiology, progress or treatment.  The mission of SSRI is to raise awareness and funding for leiomyosarcoma research. Projects funded by SSRI are the full responsibility of the recipient organization. SSRI has no influence over any aspect of the projects.  Reports regarding the results and the impact of the projects are stipulated by the grant in order to provide public sharing of research information. Refer to complete details in the Full RFP document.


If you have questions regarding this RFP, please direct them in writing to